MetaVia Inc. Announces Preclinical DA-1726 Tissue Distribution Results

What Happened
MetaVia Inc. (MTVA) announced on September 9, 2026 (via a press release filed as Exhibit 99.1 in an 8‑K) results from a preclinical DA-1726 tissue distribution study. The DA-1726 Study found that DA-1726‑derived radioactivity is slowly absorbed after subcutaneous dosing, is widely distributed throughout the body, and shows the highest tissue exposure in adipose (fat) tissue. The study observed prolonged retention of radioactivity in tissues through the final 144‑hour assessment and only minimal radioactivity in the central nervous system.

Key Details

• Study: DA-1726 tissue distribution study; results announced September 9, 2026.
• Route: Subcutaneous administration; radioactivity was slowly absorbed.
• Tissue exposure: Greatest exposure outside injection site in abdominal, subcutaneous and brown fat, and liver; highest overall in adipose tissue.
• Duration: Prolonged tissue retention observed through 144 hours; tissue-to-plasma ratios increased over time.
• CNS penetration: Only minimal radioactivity detected in central nervous system.
• Disclosure: Press release incorporated by reference in the 8‑K; filing includes standard forward‑looking statement cautions.

Why It Matters
For investors, these preclinical results support MetaVia’s development rationale for DA-1726, indicating a long tissue residence consistent with a once‑weekly dosing profile and limited brain penetration typical of peptide therapies. These findings are preclinical and not predictive of clinical outcomes, but they provide evidence relevant to the drug’s pharmacokinetic profile and potential dosing strategy going into clinical development.